Pharmacy Corporation of America v. Askari

CourtDistrict Court, D. Delaware
DecidedSeptember 3, 2021
Docket1:16-cv-01123
StatusUnknown

This text of Pharmacy Corporation of America v. Askari (Pharmacy Corporation of America v. Askari) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pharmacy Corporation of America v. Askari, (D. Del. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

PHARMACY CORPORATION OF Civil Action No. 16-1123-RGA AMERICA/ASKARI CONSOLIDATED LITIGATION, CONSOLIDATED

MEMORANDUM OPINION

Jeffrey S. Cianciulli, WEIR & PARTNERS LLP, Wilmington, DE; Walter Weir, Jr., Steven E. Angstreich, Amy R. Brandt, Andrew Park, WEIR & PARTNERS, Philadelphia, PA; James Sawyer, LAW OFFICE OF JAMES SAWYER, Jericho, NY, Attorneys for Kaveh Askari, Onco360 Holdings 1, Inc., Onco360 Holdings 2, Inc., and Onco360 Holdings 3, Inc. Brett D. Fallon, FAEGRE DRINKER BIDDLE & REATH LLP, Wilmington, DE; Christopher G. Kelly, Stosh M. Silivos, HOLLAND & KNIGHT LLP, New York, NY; Jeremy M. Sternberg, HOLLAND & KNIGHT, Boston, MA, Attorneys for Pharmacy Corporation of America.

September 3, 2021

hohardl 4b. Andi ANDREWS, Is. DISTRICT JUDGE: Before the Court is Plaintiffs’ “Motion to Amend Judgment and/or for New Trial Pursuant to F.R.C.P 52 and 59.” (D.I. 230). I have reviewed the parties’ briefing. (D.IL. 231, 232, 233). L BACKGROUND This case is the consolidation of two related lawsuits. In one, Plaintiffs Kaveh Askari, Onco360 Holdings 1, Inc., Onco360 Holdings 2, Inc., and Onco360 Holdings 3, Inc., brought suit against Defendant Pharmacy Corporation of America. In the other, Pharmacy Corporation of America brought suit against Askari individually. The Court conducted a remote bench trial on July 6 to 8, 2020. (D.L. 218, 219, 220). Following post-trial briefing, on September 8, 2020, I issued a Trial Opinion. (D.I. 224). The Final Judgments issued on September 16, 2020. (D.I. 228, 229). Plaintiffs now move to amend Paragraph 1 of one of the Final Judgments (D.I. 229) and/or for a new trial. (D.1. 231 at 1). Il. PLAINTIFFS’ BRIEFING IS STRUCK Plaintiffs filed a brief in support of their motion (D.I. 231) that clearly violates the Local Rules. It is twenty pages long. It has no Statement of Facts. It literally has a caption with that heading (id. at 1), but what follows is the statement that in the interest of “brevity,” Plaintiffs “rely upon” the Pretrial Order, the trial transcript and exhibits and its two post-trial briefs. (/d.). That is in excess of 70 pages for the pretrial order and briefs, 635 pages for the trial transcript, and more pages than I care to count for the exhibits. The rules do not permit this. The brief is to contain a “concise statement of facts, with supporting references to the record, presenting the background to the questions at issue.” D.Del. LR 7.1.3 (c)(1)(E).

,

There are reasons for that rule. First, it forces counsel to develop a coherent statement of relevant facts. Second, it provides the Court with the source material necessary to consider the arguments a party raises. The way Plaintiffs have presented their arguments does neither. Thus, Plaintiffs not only violate the cited rule, but by purporting to rely upon 705 pages plus the exhibits, Plaintiffs also violate the rule restricting the brief to twenty pages. See D.Del. LR 7.1.3(a)(4) (“Length”). For the violations of the rules, Plaintiffs’ briefing is struck. Since there is no briefing, the motions are denied. In the interests of justice, I will nevertheless consider the multiple arguments Plaintiffs make. Il. MOTION TO AMEND FINDINGS PURSUANT TO RULE 52(b) Plaintiffs move for the Court to amend its findings under Rule 52(b) to “properly reflect the testimony regarding Net Debt at the time of the Second Call.” (D.L 231 at 2-3). Plaintiffs seek to have the Court amend its findings and “raise the Second Call purchase calculation [from $18,854,499]! to $20,976,894.” (Id. at 2-3). Defendant counters that the issues Plaintiffs raise are not “basic or essential” to the litigation as such issues are not related to a claim asserted in the complaint. (D.I. 232 at 1). Defendant argues that the “court appropriately determined that Plaintiffs proved neither a breach at the First Call...nor any failure to include shared services revenue in the EBITDA calculation.” (/d. at 2). These determinations, Defendant asserts, “properly disposed of Plaintiffs’ Second Call claims, and thus the Loan balance at the time of the Second Call is not an issue that is ‘basic or essential’ to the litigation.” (/d.). Under the Federal Rules of Civil Procedure, upon a timely motion, “the court may amend its findings — or make additional findings — and may amend the judgment

1 (See D.I. 224 at 6 [noting the purchase price calculation for the Second Call was $18,854,499]). Since Plaintiffs did not prove that $18,854,499 was the wrong amount, the judgment awarded Plaintiffs nothing,

accordingly.” Fed. R. Civ. P. 52(b). “The purpose of a Rule 52(b) motion is to ‘correct manifest errors of law or fact... .” Alcon Research Ltd. v. Barr Labs. Inc., 2012 WL 928189, at *1 (D. Del. 2012), aff'd, 745 F.3d 1180 (3d Cir. 2014) (citing Power Integrations, Inc. v. Fairchild Semiconductor Int'l, Inc., 762 F. Supp. 2d 710, 717 (D. Del. 2011)). A Rule 52(b) motion to amend is permitted “only when the issues are ‘basic or essential’ to the litigation.” Jd. (citation omitted). “Importantly, Rule 52(b) does not permit a party to get a ‘second bite at the apple,’ e.g., by relitigating old issues.” Alcon Research, 2012 WL 928189, at *1 (emphasis omitted). “The scope of a motion for reconsideration. . . is extremely limited.” Blystone v. Horn, 664 F.3d 397, 415 (3d Cir. 2011). Here, Plaintiffs have not identified a “manifest error of law or fact” that merits correction. Plaintiffs argue, instead, that the Second Call purchase price was incorrectly calculated because no debt should have been subtracted, and the judgment should be reflected to amend that. However, this is not a manifest error of law or fact, because this was not an issue at trial. In the Trial Opinion, the Court identified the remaining allegations pertaining to the Second Call: “(1) the First Call breach means that the First Call is null and void, and therefore the Second Call is also null and void,. . . or, in the alternative, (2) the First Call breach means that Defendant had to purchase 62.5% of the membership interests at Second Call.” (D.I. 224 at 8).? The Court identified that these Counts “also claim that the purchase price was incorrectly calculated because ‘revenues derived from shared services’ were not included in the EBITDA calculation.” (/d. at 8-9). Whether the Second Call purchase price was incorrectly calculated because of debt being improperly

2 Plaintiffs essentially concede that they did not raise this issue in the operative complaint. (D.I. 233 at 1- 2). Plaintiffs imply that it was “first learned at trial.” (/d. at 2), But the trial was not about accounting issues that were not raised before trial. And, I note, I am certainly unpersuaded that there was any plain error,

subtracted was not raised as an issue for trial. Therefore, it is not a “manifest error” and is not an issue that is “basic and essential” to this litigation that meets the standard for amending the judgment under Rule 52(b). Thus, Plaintiffs’ motion to amend the judgment under Rule 52(b) is denied. IV.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Pharmacy Corporation of America v. Askari, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pharmacy-corporation-of-america-v-askari-ded-2021.